Publicaciones en colaboración con investigadores/as de Gustave Roussy Cancer Campus (24)

2024

  1. Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA

    Annals of Oncology, Vol. 35, Núm. 9, pp. 805-816

  2. Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non‐Small‐Cell Lung Cancer

    Clinical Lung Cancer, Vol. 25, Núm. 3, pp. 233-243.e8

  3. Atezolizumab Combined with Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer with a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III Trial

    Journal of Clinical Oncology

  4. Biomarker Identification in Liver Cancers Using Desorption Electrospray Ionization Mass Spectrometry (DESI-MS) Imaging: An Approach for Spatially Resolved Metabolomics

    Methods in molecular biology (Clifton, N.J.), Vol. 2769, pp. 199-209

  5. Capmatinib plus nazartinib in patients with EGFR-mutated non–small cell lung cancer

    European Journal of Cancer, Vol. 208

  6. Inhibition of acyl-CoA binding protein (ACBP) by means of a GABAARγ2-derived peptide

    Cell Death and Disease, Vol. 15, Núm. 4

  7. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches

    Journal of Extracellular Vesicles, Vol. 13, Núm. 2

  8. Overall Survival From the EORTC LCG-1613 APPLE Trial of Osimertinib Versus Gefitinib Followed by Osimertinib in Advanced EGFR-Mutant Non-Small-Cell Lung Cancer

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 42, Núm. 12, pp. 1350-1356

  9. SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer

    Annals of Oncology, Vol. 35, Núm. 1, pp. 66-76

2023

  1. Immune-checkpoint inhibition for resectable non-small-cell lung cancer — opportunities and challenges

    Nature Reviews Clinical Oncology, Vol. 20, Núm. 10, pp. 664-677

  2. MET alterations in NSCLC—Current Perspectives and Future Challenges

    Journal of Thoracic Oncology, Vol. 18, Núm. 4, pp. 419-435

  3. Molecular Epidemiology and Treatment Patterns of Patients With EGFR Exon 20-Mutant NSCLC in the Precision Oncology Era: The European EXOTIC Registry

    JTO Clinical and Research Reports, Vol. 4, Núm. 1

  4. Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial

    Annals of Oncology, Vol. 34, Núm. 5, pp. 468-476

  5. Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1

    Annals of Oncology, Vol. 34, Núm. 10, pp. 920-933

  6. Second-line treatment outcomes after progression from first-line chemotherapy plus immunotherapy in patients with advanced non-small cell lung cancer

    Lung Cancer, Vol. 178, pp. 116-122

2022

  1. Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations

    European Journal of Cancer, Vol. 167, pp. 142-148

  2. Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations

    European Journal of Cancer

2021

  1. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

2020

  1. Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment

    Lung Cancer, Vol. 150, pp. 90-96

  2. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial

    The Lancet Oncology, Vol. 21, Núm. 5, pp. 645-654